Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT-P13 SC Auto-injector vs Pre-filled Syringe in Healthy Subjects
NCT03446976Phase 1Completed
- Sponsor
- Celltrion
- Start
- Feb 2018
- Primary completion
- Jul 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of infliximab-dyyb in rheumatoid arthritis (RA), Crohn's disease, ulcerative colitis (UC) and 3 more (2 arms), sponsored by Celltrion. Primary endpoint: Pharmacokinetics of CT-P13 SC at 12 weeks. Started Feb 2018; status: completed.
02
Drugs
infliximab-dyyb
03
Conditions
rheumatoid arthritis (RA)Crohn's diseaseulcerative colitis (UC)ankylosing spondylitis (AS)psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT03446976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03446976.